{
  "context": {
    "rules": [
      "Rule1: Provided that drug X is approved, drug X is not marketed.",
      "Rule2: In cases where drug X has orphan drug designation, drug X has a rare disease indication.",
      "Rule3: Given that drug X has a rare disease indication, then whenever the clinical trial for drug X is complete, it implies that if drug X is approved, drug X is marketed.",
      "Rule4: If FDA review of drug X is conducted, then provided the clinical trial for drug X is complete, it follows that if drug X is approved, drug X is marketed.",
      "Rule5: Either FDA review of drug X is conducted or drug X has fast track designation.",
      "Rule6: Provided that drug X has fast track designation, drug X has orphan drug designation.",
      "Rule7: In cases where drug X has fast track designation, drug X has priority review.",
      "Rule8: Should drug X have priority review, then if the clinical trial for drug X is complete, it follows that if drug X is approved, drug X is marketed.",
      "Rule9: Whenever drug X has accelerated approval, then provided the clinical trial for drug X is complete, it implies that if drug X is approved, drug X is marketed.",
      "Rule10: If drug X has breakthrough therapy designation, then drug X has accelerated approval.",
      "Rule11: Provided that drug X has standard review, drug X has a complete response.",
      "Rule12: If it is not the case that fast track designation of drug X implies breakthrough therapy designation, then drug X has standard review.",
      "Rule13: In the event that drug X is not manufacturing compliant, drug X is approved."
    ],
    "facts": [
      "Fact1: The clinical trial for drug X is complete.",
      "Fact2: Drug X does not have a complete response."
    ]
  },
  "question": "Drug X is manufacturing compliant."
}